Meeting Archives
Chemotherapy Foundation Symposium XXIII
November 2-5, 2005
Marriott Marquis Hotel , New York , NY
Innovative Cancer Therapy for Tomorrow
Brain Tumors | Breast Cancer | GI Cancers
GU Cancers | Gynecological Cancer | Head and Neck Cancer
Hematology | Lung Cancer | Melanoma
Diverse Therapeutic Strategies | Oncology Issues
| Title | Presenter | |
|---|---|---|
| Brain Tumors | ||
| The Role of AGT in Guiding Therapy of Malignant Glioma | Henry S. Friedman, M.D. | View Presentation |
| Back to Top | ||
| Breast Cancer Moderators: Larry Norton, George Raptis |
||
| Emerging Trends: Targeted Therapy in Breast Cancer | Clifford A. Hudis, M.D. | View Presentation |
| Exemestane or Tamoxifen for Early Breast Cancer | Stephen Jones, M.D. | View Presentation |
| Clinical Applications of Gene Expression Data in Breast Cancer | Terry Mamounas, M.D. | View Presentation |
| Ezra M. Greenspan Memorial Lecture Biology of Breast Cancer: Through the Lens of Recent Clinical Trial Results | Larry Norton, M.D. | View Presentation |
| Pegylated Liposomal Doxorubicin and Hyperthermia for Chest Wall Metastases | John Park, M.D. | View Presentation |
| Antiangiogenesis in Breast Cancer | Mark Pegram, M.D. | View Presentation |
| Letrozole in Adjuvant Breast Cancer | Nicholas Robert, M.D. | View Presentation |
| Zarnestra in Breast Cancer | Joseph A. Sparano, M.D. | View Presentation |
| Ixabepilone in Breast Cancer | Sandra M. Swain, M.D. | View Presentation |
| Genomic Profiling as Predictors of Response in Breast Cancer | Debu Tripathy, M.D. | View Presentation |
| Neoadjuvant Trastuzumab-Based Regimens | Eric P. Winer, M.D. | View Presentation |
| Treatment of Trastuzumab-Refractory Breast Cancer | Eric P. Winer, M.D. | View Presentation |
| Advances in Therapy of Breast Cancer | Norman Wolmark, M.D. | View Presentation |
| Back to Top | ||
| GI Cancers Moderators: Michael Goldsmith, Howard Hochster, Steven Itzkowitz |
||
| Docetaxel Regimens in Gastric Cancer | Jaffer Ajani, M.D. | View Presentation |
| Panitumumab in GI Cancers | Al Benson, M.D. | View Presentation |
| Chemotherapy and Biologics in Metastatic Colorectal Cancer | Edward Chu | View Presentation |
| Clinical Trials in Esophagogastric Cancer | Peter Enzinger | View Presentation |
| Advances in Therapy of Colon Cancer | Daniel Haller, M.D. | View Presentation |
| PTK/ZK: A Small Molecule Inhibitor or VEGF-receptors | J. Randolph Hecht, M.D. | View Presentation |
| Bevacizumab with Oxaliplatin Combinations in Colorectal Cancer | Howard Hochster, M.D. | View Presentation |
| Options in the Management of Metastatic Colorectal Cancer | Paulo Hoff, M.D. | View Presentation |
| Treatment of Imatinib-Resistant GIST | Robert Maki, M.D. | View Presentation |
| Current Treatment Options in Rectal Cancer | Bruce D. Minsky, M.D. | View Presentation |
| Gemcitabine and Erlotinib in Pancreatic Cancer | Malcolm Moore, M.D. | View Presentation |
| Sequence Strategies in Colorectal Cancer | Leonard Saltz, M.D. | View Presentation |
| Antiangiogenesis Therapy for Hepatocellular Carcinoma | Jonathan Schwartz, M.D. | View Presentation |
| Back to Top | ||
| GU Cancers Moderator: Anna Ferrari |
||
| Sorafenib: Clinical Trials in Kidney Cancer | Ronald Bukowski | View Presentation |
| Viral Vaccines in Prostate Cancer | Robert DiPaola, M.D. | View Presentation |
| SU11248 in Metastatic Renal Cell Carcinoma | Daniel George, M.D. | View Presentation |
| Bevacizumab/erlotinib in Advanced Renal Cell Cancer | John D. Hainsworth, M.D. | View Presentation |
| Targeted Approach to Renal Cell Carcinoma Therapy | Robert Motzer, M.D. | View Presentation |
| Atrasentin in Metastic High Risk Prostate Cancer | Daniel Petrylak, M.D. | View Presentation |
| Docetaxel Combination Therapy in Prostate Cancer | Daniel Petrylak, M.D. | View Presentation |
| Zoledronic Acid vs. Placebo for Prostate Cancer Bone Loss | Christopher Ryan, M.D. | View Presentation |
| RAD001 in Prostate Cancer | Howard Scher, M.D. | View Presentation |
| Vinflunine in Urothelial Cancer | David Vaughn, M.D. | View Presentation |
| Back to Top | ||
| Gynecological Cancers Moderators: Franco Muggia, Tamar Safra |
||
| Endometrial Cancer: New Ways of Integrating Anthracyclines, Taxanes and Platinums | Eleni Andreopoulou, M.D. | View Presentation |
| Thalidomide and Topotecan for the Treatment of Recurrent Ovarian Cancer | Levi Downs Jr. | View Presentation |
| Inhibitors of Angiogenesis in Ovarian Cancer | Agustin A. Garcia, M.D. | View Presentation |
| Reducing Chemo-Resistance: Clinical Data TLK-286 | John Kavanagh, M.D. | View Presentation |
| Intraperitoneal Chemotherapy of Ovarian Cancer: Control of Serosal Disease Leads to Improved Survival | Franco Muggia, M.D. | View Presentation |
| A Role for Intraperitoneal Topotecan in Peritoneal Cancers | Howard Muntz, M.D. | View Presentation |
| Weekly Topotecan in Recurrent and Persistent Ovarian Cancer | Tamar Safra, M.D. | View Presentation |
| Relapsed Platinum Resistant Ovarian Cancer | David Spriggs, M.D. | View Presentation |
| Back to Top | ||
| Head and Neck Cancer | ||
| Organ and Function Preservation in Head and Neck Cancer: Current Status and Future Directions | Louis B. Harrison, M.D. | View Presentation |
| Clinical Experience: Abraxane | Michael J. Hawkins, M.D. | View Presentation |
| Update on EGFR Inhibitors and Radiation in the Management of Head and Neck Cancer | David Raben, M.D. | View Presentation |
| Back to Top | ||
| Hematology Moderators: Janet Cuttner, Janice Gabrilove, Jonathan Licht |
||
| Lenalidomide in Multiple Myeloma | Kenneth C. Anderson, M.D. | View Presentation |
| Ixabepilone in Non-Hodgkin's Lymphoma | Howard Burris, III | View Presentation |
| Pentostatin Combination Therapy for Low-Grade Non-Hodgkin's Lymphomas | Nicholas J. Di Bella, M.D. | View Presentation |
| Motexafin Gadolinium (Xcytrin) Trials in Non-Hodgkins Lymphoma | Andrew Evens, M.D. | View Presentation |
| MDS: Emerging Treatment Options | Eric J. Feldman, M.D. | View Presentation |
| New Options in Acute Leukemia | James Foran, M.D. | View Presentation |
| TBI Pentostatin and Photopheresis in Lymphoma | Francine Foss, M.D. | View Presentation |
| AMN107 Therapy of Imatinib-Refractory Leukemia | Frank Giles, M.D. | View Presentation |
| Troxacitabine in Refractory AML | Frank Giles, M.D. | View Presentation |
| Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia | John D. Hainsworth, M.D. | View Presentation |
| Emerging Role of Pixantrone in NHL | Paul Hamlin, M.D. | View Presentation |
| Bortezomib in Early Myeloma | Sundar Jagannath, M.D. | View Presentation |
| Previously Untreated Patients with Indolent Lymphoma | Robin Joyce, M.D. | View Presentation |
| Pentostatin Combination Therapy in Chronic Lymphocytic Leukemia | Neil E. Kay, M.D. | View Presentation |
| Idiotype Vaccine Therapy in Lymphoma | John Leonard, M.D. | View Presentation |
| Prophylactic Use of Colony-Stimulating Factors: Guidelines | Gary Lyman, M.D. | View Presentation |
| Cloretazine in AML | Susan O'Brien, M.D. | View Presentation |
| Evolving Strategies in Colorectal Cancer | Michael O'Connell, M.D. | View Presentation |
| Preventing Neutropenia: Current Data | Michael E. Rader, M.D. | View Presentation |
| BCL-2 Antisense Therapy in Chronic Lymphocytic Leukemia | Kanti R. Rai, M.D. | View Presentation |
| Emerging Role of Bortezomib in Relapsed and Refractory Myeloma | Paul G. Richardson, M.D. | View Presentation |
| Arsenic Trioxide in AML | Gail Roboz, M.D. | View Presentation |
| CLL: Front Line Combination Therapies | William G. Wierda, M.D., Ph.D. | View Presentation |
| Darbepoetin: Current Status of Long Acting Erythropoietin | Lee Schwartzberg, M.D. | View Presentation |
| Back to Top | ||
| Lung Cancer Moderators: Philippe Chahinian, Roman Perez-Soler |
||
| 2005: Adjuvant Therapy of Non-Small Cell Lung Cancer | Paul A. Bunn, Jr., M.D. | View Presentation |
| Telcyta in NSCLC | Howard Burris, III, M.D. | View Presentation |
| Unique Role of Docetaxel in Combined Modality Therapy of NSCLC | David Gandara, M.D. | View Presentation |
| Angiogenesis Inhibition in NSCLC | Roy Herbst, M.D., Ph.D. | View Presentation |
| Liposomal MUCI Vaccine in NSCLC: A Randomized Study | Nevin Murray, M.D. | View Presentation |
| ZD6474 in Second Line Treatment of NSCLC | Ronald Natale, M.D. | View Presentation |
| Phase 1/2 Study of ABI-007 (Abraxane) in Chemotherapy: Naive Advanced NSCLC | Naiyer A. Rizvi, M.D. | View Presentation |
| Pemetrexed in SCLC | Mark A. Socinski, M.D. | View Presentation |
| Xyotax in NSCLC and Other Solid Tumors | Mark A. Socinski, M.D. | View Presentation |
| Back to Top | ||
| Melanoma | ||
| BCL-2 Antisense Therapy in Melanoma | Frank G. Haluska, M.D., Ph.D. | View Presentation |
| Phase II Study of Abraxane in Metastatic Malignant Melanoma | Evan Hersh, M.D. | View Presentation |
| Sorafenib with Carboplatin/Paclitaxel in Advanced Melanoma | Jeffrey Sosman | View Presentation |
| Back to Top | ||
| Diverse Therapeutic Strategies Moderators: Seymour Cohen, Lewis Silverman |
||
| Clinical Update: Lapatinib (GSK572016) A Dual EGFR-TK Inhibitor | Howard Burris, III | View Presentation |
| Epigenetics in Cancer | Guillermo Garcia-Manero, M.D. | View Presentation |
| Enzastaurin in Solid Tumors | Roy Herbst, M.D., Ph.D. | View Presentation |
| Phase II Study of SU11248 in Neuroendocrine Tumors | Matthew H. Kulke, M.D. | View Presentation |
| Dalteparin (Fragmin): Treatment of Cancer-Associated Thromboembolism | Howard A. Liebman, M.D. | View Presentation |
| Oral Topotecan Plus Supportive Care Offers Survival Benefit Compared to Supportive Care Alone | Mary O'Brien, M.D. | View Presentation |
| Emerging Evidence on Biological Sex Differences: Is Gender Specific Therapy Warranted? | Suresh Ramaligam, M.D. | View Presentation |
| Decision Making: Prognostic and Predictive Information | Peter Ravdin, M.D. | View Presentation |
| The NCI Clinical Development Program: Novel Therapeutics Targeting Signal Transduction | John J. Wright, M.D., Ph.D. | View Presentation |
| Back to Top | ||
| Oncology Issues Moderators: Seymour Cohen, Larry Norton, Lewis Silverman |
||
| Defining Success of Oncology Drugs | Vicki Goodman, M.D. | View Presentation |
| Defining, Measuring and Paying for Quality of Cancer Care | Deborah Schrag, M.D. | View Presentation |
| Back to Top | ||
